Neoplasms
The Department of Medical Oncology at Multiprofile Hospital For Active Treatment Dobrich AD is evaluating new endocrine strategies for ER+/HER2- Early Breast Cancer, aiming to improve recurrence prevention after standard adjuvant therapy.
- Extended endocrine therapy with camizestrant
- Combination of camizestrant and abemaciclib
- Adjuvant treatment sequencing after two years of standard therapy
Ten investigators are conducting these studies in Dobrich, Bulgaria, to determine whether novel oral agents can surpass current hormonal regimens.
Nutritional and Metabolic Diseases
Researchers are also focusing on Obesity, testing a new peptide therapy for its impact on cardiovascular safety and weight reduction in individuals with excess body weight.
- Cardiovascular outcome assessment in overweight participants
- Evaluation of non‑inferiority versus placebo for major adverse cardiac events
- Integration of metabolic risk reduction with weight management
The same clinical team of ten investigators is leading this trial to explore whether the investigational drug can offer a safer alternative for patients struggling with obesity.
